Take the $1 billion challenge!
Inspired by OHSU's mission to end cancer as we know it, Phil and Penny Knight issued a surprise $1 billion, two-year challenge on Sept. 20, 2013 at a fundraising gala for the Knight Cancer Institute. The Knights will give OHSU $500 million if we raise an additional $500 million by Sept. 2015. Help us reach our goal by making a gift to Doernbecher's pediatric cancer program today.
About the Doernbecher cancer program
Doernbecher houses Oregon’s most comprehensive children’s cancer center, including an inpatient unit, outpatient clinic and infusion center. Advanced treatment programs in leukemia, neuro-oncology, stem cell transplantation, and developmental therapeutics ensure that children with cancer don’t have to leave Oregon to receive the most effective treatments.
Doernbecher doctors were the first to use the drug Gleevec to treat children with chronic myeloid leukemia. Developed at OHSU, Gleevec is the world’s first drug able to target cancerous cells while leaving normal cells alone.
With philanthropic investment, Doernbecher can serve more children, give hope to more families, and discover new ways to eradicate pediatric cancers.